Contrasting DBV TECHNOLOGIE/S (NASDAQ:DBVT) & Momenta Pharmaceuticals (NASDAQ:MNTA)
DBV TECHNOLOGIE/S (NASDAQ:DBVT) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
This table compares DBV TECHNOLOGIE/S and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
46.4% of DBV TECHNOLOGIE/S shares are held by institutional investors. Comparatively, 98.4% of Momenta Pharmaceuticals shares are held by institutional investors. 15.3% of DBV TECHNOLOGIE/S shares are held by insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
DBV TECHNOLOGIE/S has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.
Earnings and Valuation
This table compares DBV TECHNOLOGIE/S and Momenta Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DBV TECHNOLOGIE/S||$17.17 million||33.06||-$196.14 million||($3.39)||-2.78|
|Momenta Pharmaceuticals||$75.59 million||15.50||-$176.06 million||($2.03)||-5.85|
Momenta Pharmaceuticals has higher revenue and earnings than DBV TECHNOLOGIE/S. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV TECHNOLOGIE/S, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for DBV TECHNOLOGIE/S and Momenta Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DBV TECHNOLOGIE/S presently has a consensus price target of $15.28, indicating a potential upside of 62.39%. Momenta Pharmaceuticals has a consensus price target of $23.54, indicating a potential upside of 98.29%. Given Momenta Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Momenta Pharmaceuticals is more favorable than DBV TECHNOLOGIE/S.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.